Yamamoto Y, Shirono H, Kono K, Ohashi Y., Immunopotentiating activity of the water-soluble lignin rich fraction prepared from LEM--the extract of the solid culture medium of Lentinus edodes mycelia., in Biosci Biotechnol Biochem, vol. 61, n. 11, Nov 1997, pp. 1909–12, PMID9404070.
Tochikura TS, Nakashima H, Yamamoto N, Antiviral agents with activity against human retroviruses., in J Acquir Immune Defic Syndr, vol. 2, n. 5, 1989, pp. 441–7, PMID2477523.
Spierings EL, Fujii H, Sun B, Walshe T, A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers, in J. Nutr. Sci. Vitaminol., vol. 53, n. 6, dicembre 2007, pp. 536–9, PMID18202543.
Ye SF, Wakame K, Ichimura K, Matsuzaki S, Amelioration by active hexose correlated compound of endocrine disturbances induced by oxidative stress in the rat, in Endocr Regul, vol. 38, n. 1, marzo 2004, pp. 7–13, PMID15147233.
Ye SF, Ichimura K, Wakame K, Ohe M, Suppressive effects of Active Hexose Correlated Compound on the increased activity of hepatic and renal ornithine decarboxylase induced by oxidative stress, in Life Sci., vol. 74, n. 5, dicembre 2003, pp. 593–602, PMID14623030.
Mach CM, Fugii H, Wakame K, Smith J, Evaluation of active hexose correlated compound hepatic metabolism and potential for drug interactions with chemotherapy agents, in J Soc Integr Oncol, vol. 6, n. 3, 2008, pp. 105–9, PMID19087767.
Ritz BW, Nogusa S, Ackerman EA, Gardner EM, Supplementation with active hexose correlated compound increases the innate immune response of young mice to primary influenza infection, in J. Nutr., vol. 136, n. 11, novembre 2006, pp. 2868–73, PMID17056815.
Matsui Y, Uhara J, Satoi S, et al., Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study, in J. Hepatol., vol. 37, n. 1, luglio 2002, pp. 78–86, PMID12076865.
Cowawintaweewat S, Manoromana S, Sriplung H, et al., Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment, in Asian Pac. J. Allergy Immunol., vol. 24, n. 1, marzo 2006, pp. 33–45, PMID16913187.
Nimura H, Mitsumori N, Takahashi N,, [S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer], in Gan to Kagaku Ryoho., vol. 33, n. 1, Jun 2006, pp. 106–9, PMID16897983.
Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K., A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group., in Hepatogastroenterology., vol. 46, n. 28, 1999, pp. 2662–8, PMID10522061.
Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J, Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer, in Anticancer Res., vol. 29, n. 7, luglio 2009, pp. 2739–45, PMID19596954.
Hazama S, Watanabe S, Ohashi M, et al., Efficacy of Orally Administered Superfine Dispersed Lentinan ({beta}-1,3-Glucan) for the Treatment of Advanced Colorectal Cancer, in Anticancer Res., vol. 29, n. 7, luglio 2009, pp. 2611–7, PMID19596936.
Kataoka H, Shimura T, Mizoshita T, et al., Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life, in Hepatogastroenterology, vol. 56, n. 90, 2009, pp. 547–50, PMID19579640.
Isoda N, Eguchi Y, Nukaya H, et al., Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma, in Hepatogastroenterology, vol. 56, n. 90, 2009, pp. 437–41, PMID19579616.
Shimizu K, Watanabe S, Watanabe S, et al., Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer, in Hepatogastroenterology, vol. 56, n. 89, 2009, pp. 240–4, PMID19453066.